LILRB4 and neoplasm: First, NGM821 is an antagonist antibody designed to prevent ILT3 (LILRB4) on suppressive myeloid cells from interacting with fibronectin in the tumor microenvironment, a “myeloid checkpoint.” It is being given alone and in combination with pembrolizumab in advanced solid tumors including mUC.